Skip to content

Orion Group Interim Report 1-9/2003

The period includes about EUR 7.3 million in non-recurrent costs related to adaptation measures underway in Orion Pharma.
 
In September, the sales of the new Parkinson's disease drug Stalevo started according to plan in the US, and in October the product received an EU-wide marketing authorisation.
 
The cosmetics division Noiro was divested on 1 October. The full-year profit of the Group will be considerably lower than that for 2002. Orion Pharma will show improved profitability next year.
 
The figures in this Interim Report have not been audited.
The figures in the parentheses refer to those of the comparative period.
 
The percentages have been calculated from more exact figures than the published ones.
 
Orion Corporation
 
Jukka Viinanen                        Jari Karlson
President and CEO                        CFO
 
Contact persons:
Jukka Viinanen, President and CEO, phone +358 10 429 3710   
             
Jari Karlson, CFO, phone +358 10 429 2883, gsm +358 50 429 2883
 
A press conference on this Interim Report will be held today, Wednesday 5 November 2003 starting at 10.30 am, at the VR Auditorium in Helsinki. The language of the occasion is Finnish. Documents will be available also in English.
 
Orion cordially invites investors and company analysts to a Capital Markets Day to be held in London on Wednesday, 26 November 2003. The programme of the event is available on Orion's homepage www.orion.fi, where also a registration facility is provided. 
 
The full report including tables can be downloaded from the following link.
 
Orion's publication schedule for 2004
 
Financial Statements Bulletin for 2003
Friday, 13 February 2004 at 8.30 am
 
Interim Report 1-3/2004
Tuesday, 18 May 2004 at 8.30 am
 
Interim Report 1-6/2004                 
Tuesday,10 August 2004 at 8.30 am
 
Interim Report 1-9/2004
Tuesday, 9 November 2004 at 8.30 am
 
The 2003 Annual Report will be mailed to registered shareholders and subscribers during week 11/2004.
The Annual General Meeting is planned to be held on Monday, 22 March 2004, starting at 5.00 o'clock pm. 

The reviews, reports and the related presentation material will be available on the Group homepage instantly upon publication. The homepage http://www.orion.fi  also provides an archive of earlier publications.
 
The 'Releases and Publications' section of the homepage also provides a facility for registration on the company's mailing lists for publications and news releases.